Wyles, D., Brau, N., Kottilil, S., Daar, E., Workowski, K., Luetkemeyer, A., … Sulkowski, M. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study. In Journal of Hepatology (Vol. 64, pp. S188–S189). Elsevier BV. https://doi.org/10.1016/s0168-8278(16)00129-x

Wyles, D., N. Brau, S. Kottilil, E. Daar, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study.” In Journal of Hepatology, 64:S188–89. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)00129-x.

Wyles D, Brau N, Kottilil S, Daar E, Workowski K, Luetkemeyer A, et al. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study. In: Journal of Hepatology. Elsevier BV; 2016. p. S188–9.

Wyles, D., et al. “Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study.” Journal of Hepatology, vol. 64, no. 2, Elsevier BV, 2016, pp. S188–89. Crossref, doi:10.1016/s0168-8278(16)00129-x.

Wyles D, Brau N, Kottilil S, Daar E, Workowski K, Luetkemeyer A, Adeyemi O, Ruane P, Doehle B, Huang KC, Osinusi A, McNally J, Brainard D, McHutchison J, Naggie S, Sulkowski M. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study. Journal of Hepatology. Elsevier BV; 2016. p. S188–S189.